About meM. Giuliani & Co. is an investment advisor firm that provides financial advisory to a broad client. We offer a better way to support our clients by providing uncompromised advice and world-class solutions that create lasting relationships.
Joined 2 years ago
The merger with Monsanto continues to move forward. We believe that the merger can create a well-integrated society.
Interesting are the Eurex options. The CALL maturing June 2017 and € 100 strike, pays 6.40 euro. Also on 4 May will be paid the dividend of at least € 2.50.
Bad news for the bank: it would have a Tier 1 capital €3bn shortfall to the company target of 12.5%, and a leverage ratio of 3.9%, resulting in an €8bn shortfall to the target of 4.5%. So that means that is needed a "monstre" capital increase. DB seems to be very riskier then Lehman Bros., because the institutional ...
Still too many risks on the Italian Index; with the approach of the referendum it could suffer a sharp increase in volatility. Our medium- term targets remain unchanged. No economic growth, public debt continues to increase, and deficit is next to lose control. The situation of MPS and the overall banking sector ...
At this price the dividend yeld is 3.50%: it is a proxy of high grade bond and we think that the split between the core human pharma and the rest of the Group probably could come in late 2016.
Strong financial position.
Air Liquide has been growing the same business – gases for industry and health – for more than 100 years. This business is organized into several activities that are linked by an industrial logic, a source of synergies and optimization.
Last dividend @ 2.60 euro, for a yeld of 2.75%
The pair is correlated with oil, we think a pull back of the oil price in area 49/51 $ will move the pair in 69.00/68.00 area. The trend continue to be in favor of the Ruble, thanks to the medium term target of oil.
We think the company has a above average capital gains return. The comèany has taken a lot of debt, and we belive that that debt will be used soon to make an acquisition. Potential target is Shire Pharma.